Skip to main content
Asymchem Laboratories (Tianjin) Co., Ltd. logo

Asymchem Laboratories (Tianjin) Co., Ltd. — Investor Relations & Filings

Ticker · 002821 ISIN · CNE100002BZ6 LEI · 8368002CY8G4Q85YRQ60 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,711 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002821

About Asymchem Laboratories (Tianjin) Co., Ltd.

https://www.asymchem.com.cn

Asymchem Laboratories (Tianjin) Co., Ltd. is a global Contract Development and Manufacturing Organization (CDMO) providing comprehensive solutions across the drug development lifecycle. The company specializes in integrated CMC services for small molecule pharmaceuticals, spanning from early-stage preclinical research to large-scale commercial production. Asymchem is recognized for its advanced technology platforms, particularly in green chemistry, continuous flow manufacturing, and biocatalysis. Its service portfolio includes emerging modalities such as oligonucleotides, peptides, and biologics. By leveraging innovative chemical engineering and process optimization, the company supports pharmaceutical and biotechnology firms in accelerating drug candidates to market while ensuring high quality and cost-efficiency through integrated research and manufacturing capabilities.

Recent filings

Filing Released Lang Actions
H股公告：证券变动月报表
Regulatory Filings Classification · 90% confidence The document is an HKEX FF301 monthly Securities Movement Report (“月報表”) filed under the Listing Rules (Chapter 19B) detailing legal/registered share capital, issued and treasury shares movement, public float confirmation, and share arrangement schedules. It is a periodic regulatory compliance return rather than a corporate annual/interim report, management commentary, earnings release, or one‐off capital raising announcement. It does not contain substantive financial statements or one‐off share issue events but serves as a routine regulatory filing. Therefore it falls under Regulatory Filings (RNS).
2026-06-02 Chinese
《凯莱英医药集团（天津）股份有限公司章程》
Governance Information Classification · 95% confidence The document is the full text of the company’s “章程” (Articles of Association), detailing the internal rules, shareholder rights, board and management structure, share capital provisions, meeting procedures, etc. This is a governance charter, not an announcement of results, not an earnings release or annual report. It directly matches the definition of Governance Information (CGR).
2026-04-17 Chinese
凯莱英医药集团（天津）股份有限公司2026年第一次临时股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document is a legal opinion issued by Beijing DeHeng Law Offices concerning the convening, procedures, and outcomes of the company’s 2026 extraordinary general shareholders’ meeting and class meetings. It verifies the legality of the meeting and discloses detailed voting results for each resolution. Although framed as a law firm opinion, its primary substance is the formal declaration of voting results. Under our taxonomy, this aligns best with “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-04-17 Chinese
非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation and summary table regarding non-operating fund occupation and other related party fund transactions for the fiscal year 2025 of 凯莱英医药集团（天津）股份有限公司. It includes audited financial data and references an audit report issued by a certified public accounting firm (Ernst & Young Hua Ming). The document is focused on compliance with regulatory guidelines concerning fund occupation and related party transactions, and it contains substantive financial data and analysis for the specified fiscal year. It is not a general annual report, earnings release, or a simple announcement. It is a specialized audit-related report on specific financial matters, which fits the category of Audit Report / Information (AR). The document length (5105 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-03-30 Chinese
2025年度独立董事述职报告(谢维恺)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025, detailing the independent director's duties, attendance, committee participation, communication with auditors, and focus areas during the term. It includes no financial statements or substantive financial data but rather a narrative of the director's activities and compliance with governance rules. The document length is 3782 characters, which is relatively short and focused on governance and director duties rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. It is a report by an independent director about their work and compliance, which fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles. Therefore, the classification is MANG with high confidence.
2026-03-30 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report' for 凯莱英医药集团（天津）股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including governance structure, risk management, financial reporting controls, and internal control deficiencies. The document is a detailed report on internal control evaluation rather than an announcement or certification. It does not contain quarterly or annual financial statements but focuses on internal control assessment and compliance with internal control standards. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. The document length (6411 characters) and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-03-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.